MuscleLedger

Oral Peptides for Muscle Growth: What Oral Means

The gut digests peptides. The one oral peptide drug on the market delivers 0.4-1% of its dose, and most oral peptides sold for muscle are not peptides at all.

MuscleLedger Editorial · Published 2026-09-06

Search interest in oral peptides is rising faster than almost anything else in this niche — one roundup variant is up several thousand per cent year on year. The appeal is obvious: the same promise without the needle. The obstacle is equally obvious once stated, which is why product pages rarely state it. The human gut exists to break peptides into amino acids. This page explains what "oral" costs in pharmacological terms, using the one oral peptide drug that succeeded as the benchmark, and sorts the category into the three things it actually contains. It is research journalism about research compounds and contains no usage guidance, per our editorial standards.

The benchmark: what a successful oral peptide looks like

Oral semaglutide is the proof that the route is possible and the measure of how hard it is. It is a GLP-1 analogue — a 31-amino-acid peptide — formulated as a tablet with salcaprozate sodium (SNAC), an absorption enhancer that shifts local pH and membrane permeability so that a fraction of the dose crosses the stomach lining before enzymes reach it.

The FDA-approved prescribing information states the result directly. Absorption "predominantly occurs in the stomach", and "semaglutide estimated absolute bioavailability was approximately: 0.4% to 1% after oral administration of 3 mg, 7 mg and 14 mg of RYBELSUS", and "1% to 2%" for the 1.5, 4 and 9 mg strengths of the related oral tablet (DailyMed, SPL version 14, published 2026-08-19).

Read that number the right way round. It is not a failure. It is what a pharmaceutical company achieves after a full development programme, with a purpose-built permeation enhancer, gastric-targeted delivery and dose sizes set an order of magnitude above the injectable to compensate. Roughly one per cent is the state of the art for putting an intact therapeutic peptide through a human gut wall.

The trials that established it are worth naming for a second reason. The first-in-human study gave oral semaglutide to 135 healthy males; the ten-week multiple-dose study enrolled 84 healthy males plus 23 males with type 2 diabetes (Granhall et al., Clinical Pharmacokinetics 2019). No women appear in either. MuscleLedger's page on the research gap in women counts how common that pattern is across this whole field.

The three things sold as "oral peptides"

1. Molecules that are not peptides. MK-677, sold as ibutamoren, is the leading example. It is a small-molecule ghrelin-receptor agonist with no peptide bonds, which is exactly why it survives the stomach when injectable secretagogues would not. It has a real human literature — PubMed returns 63 records and 15 randomised trials as of 2026-09-06 — and it is orally active. It is not an oral peptide, and every list that groups it with one is making a category error that flatters the rest of the list. Our evidence ledger scores it 2 out of 5 and says in the row that it is not a peptide.

2. Peptides with no human absorption data. BPC-157 is the case that matters here, because "stable gastric pentadecapeptide" appears in its own literature and is read by sellers as a claim about oral dosing. Rat work has administered it orally; PubMed returns 18 records for BPC-157 crossed with oral administration or gavage. What is absent is any published pharmacokinetic study in people. Searching BPC-157 against pharmacokinetics or bioavailability returns five records as of 2026-09-06, and the two human-indexed ones are a narrative review and an editorial rather than a study. The review itself, published in the International Journal of Molecular Sciences in 2026, puts the position carefully: "Although animal data indicate favorable safety and pharmacokinetics, human research remains limited to small pilot studies" (Yuan et al., IJMS 2026, PMC13026520). Nobody has measured what a swallowed dose does in a human bloodstream.

3. Food-derived peptide fragments that genuinely are absorbed. Collagen hydrolysate is the honest entry in this category. It is not absorbed as intact collagen — it is cleaved to di- and tripeptides, two of which, prolyl-hydroxyproline and hydroxyprolyl-glycine, have been measured in human peripheral blood after ingestion. PubMed returns 42 records for collagen peptides crossed with those markers in blood, plasma or serum. The clinical trial most often cited for downstream effects was conducted by researchers at a gelatin manufacturer's peptide division, which the paper states in its author affiliations (Inoue et al., Journal of the Science of Food and Agriculture 2016). Real absorption, modest effects, and a literature with a commercial interest attached that is at least declared.

Why bioavailability decides the argument

A compound that does not reach the bloodstream cannot act systemically, whatever its mechanism. That single sentence disposes of most of this category without any need to argue about whether the mechanism works.

It also reframes what a fair claim would look like. If an oral formulation of a research peptide delivered even one per cent — matching a drug with a decade of formulation science behind it — then a capsule would need roughly a hundred times the injected quantity to produce a comparable exposure. No product in this market is dosed that way, and no seller publishes a pharmacokinetic study showing what fraction arrives. The claim being made is not that a small fraction is enough; it is that the question does not need answering.

The exception that proves the rule is local action. A peptide acting on the gut lining itself does not need to be absorbed at all — and much of the BPC-157 animal literature is gastrointestinal. That is a legitimate research direction and it is not a muscle-growth claim.

What this means for the muscle question

No oral product in this category has a randomised human trial with a muscle or strength endpoint. That is also true of the injectable versions, as our evidence ledger and its ranked companion page set out row by row, so the oral question is a second obstacle stacked on an unanswered first one: whether the compound does anything, and whether any of it arrives.

The compounds with human evidence for muscle in either direction remain the boring ones. Protein and creatine are orally bioavailable because they are foods, and creatine's measured effect on muscle size is small — a pooled 0.11 in the best-controlled meta-analysis. Our comparison of creatine against the research compounds reports exactly how small, and who funded the studies.

Banned status does not change with the route

The WADA Prohibited List names substances, not formulations. BPC-157 sits at S0, thymosin-beta-4 and its derivatives including TB-500 at S2.3, and the growth-hormone secretagogues at S2.2, prohibited at all times whether swallowed, injected or applied. An athlete who takes an oral version of a prohibited compound has taken a prohibited compound. Our page on peptides and drug testing covers which tests look for them and at what sensitivity.

What would change this page

A published pharmacokinetic study in humans for any orally sold research peptide, reporting an absolute bioavailability figure the way the semaglutide label does. One number would move this whole category from assertion to measurement. It has not been published for any of them.

Sources and dates

Frequently asked questions

Do oral peptides work for muscle growth?

No product in this category has a randomised human trial with a muscle or strength endpoint, and the pharmacology sets a hard prior against most of them. Peptides are digested by the same enzymes that break down dietary protein. The only oral peptide drug in this hormone class to reach market needs a dedicated absorption enhancer and still delivers an estimated 0.4% to 1% of its dose into circulation. An unformulated capsule has no published pharmacokinetic evidence that it delivers a systemic dose at all.

Why can semaglutide be taken as a tablet but not other peptides?

Because a great deal of formulation science was applied to it. The tablet is co-formulated with salcaprozate sodium, an absorption enhancer that raises local pH and permeability so that a fraction of the dose crosses the stomach lining intact. Even so, the prescribing information puts the estimated absolute bioavailability at approximately 0.4% to 1% for the 3, 7 and 14 mg tablets and 1% to 2% for the 1.5, 4 and 9 mg tablet strengths of the related product. The route works; it works at roughly one percent.

Is MK-677 an oral peptide?

No. MK-677, also called ibutamoren, is a small-molecule ghrelin-receptor agonist, not a peptide. That is precisely why it is orally active where the injectable secretagogues are not — there are no peptide bonds for digestive enzymes to cleave. It is routinely sold and discussed as an oral peptide, and our evidence ledger flags the same category error: it scores 2 out of 5 there, and the score is about its evidence, not its route.

What about oral BPC-157 capsules?

BPC-157 is described in its own literature as a stable gastric pentadecapeptide, and rat studies have administered it orally. What does not exist is a published pharmacokinetic study in people by any route: PubMed returns five records for BPC-157 crossed with pharmacokinetics or bioavailability as of 2026-09-06, and the two human-indexed ones are a review and an editorial. A 2026 review notes that human research on the compound remains limited to small pilot studies.

Are any oral peptides actually absorbed?

Collagen peptides, as small fragments rather than intact chains. Prolyl-hydroxyproline and hydroxyprolyl-glycine, two dipeptides from collagen hydrolysate, have been measured in human peripheral blood after ingestion. That is real absorption of real peptide fragments — and it is a food, the evidence for its effects on muscle is modest, and much of the research is conducted by collagen manufacturers, which the papers disclose.

Are oral versions banned in sport?

Route of administration does not appear anywhere in the WADA Prohibited List. BPC-157 is prohibited at S0, thymosin-beta-4 derivatives at S2.3 and the growth-hormone secretagogues at S2.2, whether swallowed or injected. An oral formulation of a prohibited substance is a prohibited substance.